Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 7/20 | 0.61 |
| ▸ | GPBAR1 | Q8TDU6 | 4/20 | 0.57 |
| ▸ | LMNA | P02545 | 3/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.57 |
| ▸ | MEN1 | O00255 | 3/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | G6PD | P11413 | 3/20 | 0.57 |
| ▸ | SHBG | P04278 | 2/20 | 0.57 |
| ▸ | SERPINA6 | P08185 | 2/20 | 0.57 |
| ▸ | HSD17B3 | P37058 | 2/20 | 0.57 |
| ▸ | AKR1B10 | O60218 | 2/20 | 0.57 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.52 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20444117 | 0.90 | CYP19A1 (0.58) | CYP19A1GPBAR1LMNACYP3A4MEN1 | |
| SCHEMBL4585733 | 0.86 | CYP19A1 (0.65) | CYP19A1GPBAR1LMNACYP3A4MEN1 | |
| SCHEMBL4585736 | 0.86 | CYP19A1 (0.65) | CYP19A1GPBAR1LMNACYP3A4MEN1 | |
| SCHEMBL16407340 | 0.86 | CYP19A1 (0.65) | CYP19A1GPBAR1LMNACYP3A4MEN1 | |
| SCHEMBL5694831 | 0.84 | CYP19A1 (0.67) | CYP19A1GPBAR1LMNACYP3A4MEN1 | |
| SCHEMBL16654945 | 0.84 | CYP19A1 (0.67) | CYP19A1GPBAR1LMNACYP3A4MEN1 | |
| SCHEMBL20725025 | 0.84 | CYP19A1 (0.67) | CYP19A1GPBAR1LMNACYP3A4MEN1 | |
| SCHEMBL22069477 | 0.84 | CYP19A1 (0.67) | CYP19A1GPBAR1LMNACYP3A4MEN1 | |
| SCHEMBL5694830 | 0.84 | CYP19A1 (0.67) | CYP19A1GPBAR1LMNACYP3A4MEN1 | |
| SCHEMBL16654942 | 0.84 | CYP19A1 (0.67) | CYP19A1GPBAR1LMNACYP3A4MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3021852-B1 | NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF | SAGE THERAPEUTICS INC (US) | 2021-01-27 | — | — | EP | disclosed |
| US-20180215779-A1 | NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF | SAGE THERAPEUTICS, INC. | 2018-08-02 | — | — | US | disclosed |
| US-20160152658-A1 | NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF | SAGE THERAPEUTICS, INC. | 2016-06-02 | — | — | US | disclosed |
| US-20160152658-A1 | NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF | SAGE THERAPEUTICS, INC. | 2016-06-02 | — | — | US | disclosed |
| WO-2015010054-A2 | NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF | SAGE THERAPEUTICS, INC. (US) | 2015-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160152658-A1 | NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF | ADRA1B, AVPR1B, ADRA2B | CYP19A1 123/4885GPBAR1 150/4885LMNA 3018/4885 |
| US-20180215779-A1 | NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF | ADRA1B, AVPR1B, ADRA2B | CYP19A1 117/4885GPBAR1 177/4885LMNA 3004/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.